June 25th 2025
Marketed as Orlynvah, oral sulopenem from Iterum Therapeutics was FDA approved last fall for uncomplicated urinary tract infections (uUTIs), and has shown efficacy against infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis.
Study Insights on Aztreonam and Avibactam for Complicated Intra-Abdominal Infections
February 25th 2025Todd Riccobene, PhD, senior scientific director, Anti-Infectives and Infectious Diseases, US Medical Affairs + Health Impact at AbbVie provides more information on the newly approved antibiotic combination for these infections.
Read More
A Personnel Problem: We Need More Antimicrobial Researchers, Infectious Disease Clinicians
February 12th 2025A decreasing number of researchers and open positions for infectious disease clinicians and limited residency matches are underlying issues that should be addressed to meet the needs around antimicrobial development and clinical care. Amesh Adalja, MD, FIDSA, discusses some of the challenges behind it.
Watch
Intravenous Antimicrobials: Is It Time to Push?
January 29th 2025Intravenous (IV) push is an attractive option to administer antimicrobial therapy to patients in an efficient and effective manner in a variety of clinical settings. While many advantages to IV push administration exist, clinicians should be mindful of available literature regarding safety profiles, pharmacokinetic/pharmacodynamic characteristics, and clinical data for IV push antimicrobial administration prior to utilizing it in specific patient populations.
Read More
Early-Stage Antibiotic for Bone and Joint Infections Comparable to Standard of Care Therapy
December 9th 2024A small phase 2 study evaluated Debiopharm’s investigational antibiotic, afabicin, including its clinical response rate and safety profile of 2-3 weeks of treatment for staphylococcal bone and joint infections (BJI).
Watch
More Bugs, No Drugs: The Growing Threat of Antibiotic Resistance
December 4th 2024Amesh A. Adalja, MD, FIDSA outlined the importance of recognizing antibiotic resistance in healthcare settings, educating patients on responsible antibiotic use, and the need for new treatments and diagnostic tools.
Watch
What's New In 2024: From the CLSI Subcommittee on Antimicrobial Susceptibility Testing
November 4th 2024The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing had its series of meetings to update breakpoints for a variety of classes of antimicrobials.
Read More
Diagnostic Stewardship, Data Collection, and Incentives are Themes of UN General Assembly on AMR
October 10th 2024A holistic, multifaceted approach with a variety of stakeholders are needed to address antimicrobial resistance (AMR). The recent UN meeting on this topic looked to bring together government leaders, industry, and public health officials to discuss strategies regarding the global health crisis.
Watch